Author:
Tendeiro Rego Rita,Morris Emma C.,Lowdell Mark W.
Funder
Medical Research Council
National Institute for Health Research
Subject
Cancer Research,Transplantation,Cell Biology,Genetics (clinical),Oncology,Immunology,Immunology and Allergy
Reference130 articles.
1. Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street;Barrett;J Immunol,2015
2. Optimizing T-cell receptor gene therapy for hematologic malignancies;Morris;Blood,2016
3. Novartis. Novartis receives first ever FDA approval for a CAR-T cell therapy, KymriahTM (tisagenlecleucel, CTL019), for children and young adults with B-cell ALL that is refractory or has relapsed at least twice [press release].
4. Gilead. Kite's Yescarta™ (Axicabtagene Ciloleucel) becomes first CAR T therapy approved by the FDA for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy [press release].
5. Deconstructing the Form and Function of the TCR/CD3 Complex;Kuhns;Immunity,2006
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献